Biotech China 2014
IBD 2011: Progress and Future for Lifelong Management
ANA InterContinental Tokyo
1-12-33 Akasaka, Minato-ku Tokyo 107-0052 Japan
Tokyo, Japan
http://www.drfalkpharma.de/uploads/tx_tocfpshoperw/FS180_Preliminary_Program_neu_01.pdf
We are proud and glad to welcome all of you to FALK Symposium 180, which is held for the
first time in Japan. Inflammatory bowel disease (IBD) is a chronic intestinal disorder of
unknown etiology. The theme of this meeting is �IBD 2011: Progress and Future for Lifelong
Management�. In recent years, IBD therapeutics have been dramatically changed by the
appearance of the biologics. It also raises us a new mission to maintain long-term remission
resulting in avoiding the disability and to manage adverse effects carefully.
We are also glad that basic researchers and clinical experts of IBD in Asian countries will join
us. IBD has their highest prevalence in Western industrialized countries of Europe and North
America. However, as you know, the accumulative numbers of IBD patients have been
increasing in Japan and other Asian countries. Therefore, we will also focus on exchange
between Western countries and Asian IBD experts in this meeting.
We hope this meeting will contribute to further development of IBD management and
stimulate Asian IBD experts. We look forward to see you in Tokyo.
Please submit your poster abstract before July 31, 2011. Only one-page abstracts
not exceeding 250 words, written in English and saved in Microsoft Word format will
be accepted.
Abstracts must be submitted via our Internet Abstract Submission System
(http://www.falkfoundation.com/poster) where further information regarding the
submission format and the submission process is available.
The abstracts will be selected by the scientific organizers, preference being given to
those thematically related to one of the sessions of the program.
The accepted abstracts will be printed and distributed to the participants of the
congress together with the documents of the meeting.

http://www.drfalkpharma.de/uploads/tx_tocfpshoperw/FS180_Preliminary_Program_neu_01.pdf

Schedule of Presentations:

Friday, November 11, 2011
08:15:00 Opening remarks Toshifumi Hibi
08:15:00 Keynote Lecture I Daniel K. Podolsky
08:20:00 Difference between Western countries and Asia on genetics, diagnosis and therapeutic management of IBD Toshifumi Hibi
08:25:00 Session I Insight into genetics, immunology and regenerative science for understanding the etiology of IBD Lloyd Mayer, Tetsuhiro Chiba
09:00:00 Translating the new IBD genetics into therapy Stuart Schreiber
09:30:00 Role of innate immunity on IBD pathogenesis Ramnik J. Xavier
10:00:00 Role of adoptive immunity on IBD pathogenesis Markus F. Neurath
10:30:00 Coffee break with poster session
10:45:00 Session II Biomarkers in IBD Stephen R. Targan, Soichiro Miura
10:50:00 Intestinal bacteria & pathogenesis Arlette Darfeuille-Michaud
11:20:00 Biomarkers, impacts on pathogenesis & diagnosis Iris Dotan
11:45:00 State-of-the-Art Lecture I Tetsuhiro Chiba
11:50:00 Differential impact of the microbiota on colitis & colitis associated colorectal cancer R. Balfour Sartor
12:30:00 Lunch break with poster session
13:45:00 State-of-the-Art Lecture II R. Balfour Sartor
13:50:00 Regenerative science in IBD
14:25:00 Session III New technology for diagnosis of IBD Hisao Tajiri
14:30:00 Current topics of MRI for diagnosis of IBD Julián Panés
15:00:00 Current topics of con-focal endoscopy for diagnosis of IBD Ralf Kiesslich
15:30:00 Current topics of endoscopy for diagnosis of IBD and cancer surveillance Shinei Kudo
16:00:00 Coffee break with poster session
16:15:00 Session IV Surgery and post-operative management Iwao Sasaki
16:20:00 Current problem and topics of IBD surgery Akira Sugita
16:45:00 State-of-the-Art-Lecture III Iwao Sasaki
16:50:00 Post-operative management for IBD patients Stephen B Hanauer
17:30:00 End of afternoon session
Saturday, November 12, 2011
08:25:00 Session V Current therapeutic strategy depend on the treatment guidelines in USA, EU, Asia and Japan Edward V. Loftus
08:30:00 Introduction
08:40:00 USA Scott E. Plevy
09:00:00 EU
09:20:00 Asia (China) Jia-Ming Qian
09:40:00 Japan Fumiaki Ueno
10:00:00 Discussion and perspectives
10:30:00 Coffee break with poster session
10:45:00 Session VI Biologics and immuno-modulators: Benefit and risk for lifelong management Eduard F. Stange, Haruhiko Ogata
10:50:00 Benefit and risk of immuno-modulators for lifelong management
11:20:00 Strategy for treatment after anti-TNF failure Daan W. Hommes
11:45:00 State-of-the-Art Lecture IV Hidemi Goto
11:50:00 Side effect – Benefit and risk for lifelong management? Paul Rutgeerts
12:30:00 Lunch break with poster session
13:40:00 Poster Session
14:30:00 Presentation of Poster Prizes Markus F. Neurath
14:35:00 Session VII Special management issues of IBD Toshiyuki Matsui, Wolfgang Kruis
14:40:00 Special management for pregnant IBD patients Maria T. Abreu
15:10:00 Special management for pediatric IBD patients Marla C. Dubinsky
15:40:00 Nutritional management for IBD patients Yoshihide Fujiyama
16:10:00 Cancer surveillance for lifelong management Takahiro Watanabe
16:40:00 Coffee break with poster session
16:45:00 Keynote lecture II Toshifumi Hibi
16:50:00 Novel therapeutics for IBD William J. Sandborn
17:30:00 Concluding remarks
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.